SGLT-2i vs. GLP-1? vs Metformin? How do you balance the cost and coverage of first-line options like metformin, SGLT-2, and GLP-1s? How do you choose between SGLT-2 and GLP-1s for comorbidities like CAD or CKD? And how do you weigh their side effects and practical use?
🔹 Sponsor:
Use the code "CORE30" for 30% off: https://www.coreimpodcast.com/MKSAP
Timestamps:
(01:43) | Case 1: Managing Uncontrolled Diabetes in a 47-Year-Old Male
(07:15) | Understanding Cost and Insurance Barriers in Diabetes Care
(09:26) | Case 2: Addressing Weight Gain and Financial Stress in a 52-Year-Old Male
(14:16) | Case 3: Managing Coronary Artery Disease and CKD in a 66-Year-Old Male
(19:41) | Case 4: Severe Obesity and Pain Management in a 59-Year-Old Female
(24:19) | Case 5: High A1C and Vascular Comorbidities in a 67-Year-Old Female
(35:34) | Weighing Side Effects and Practical Use of GLP-1 and SGLT2 Inhibitors
Tags: CoreIM, Primary Care, Endocrinology, Diabetes Mellitus, Type 2 Diabetes, Type 1 Diabetes, Metformin, GLP-1, SGLT2, Insulin, CGM, A1C, DKA, Medical Education, Clinical Reasoning, Hospital Medicine